Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis - Wikidata - thesis-toulmin - TriplyDB

Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis

Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis

http://www.wikidata.org/entity/Q33404677

about

The tell-tale heart: molecular and cellular responses to childhood anthracycline exposure The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivo Intensity modulated radiotherapy for sinonasal malignancies with a focus on optic pathway preservation Liposomes as nanomedical devices Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells Synergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cells Cancer drug related cardiotoxicity during breast cancer treatment.Chemotherapy-Induced Cardiotoxicity: Pathophysiology and Prevention Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity.Non-pegylated liposomal Doxorubicin-cyclophosphamide in sequential regimens with taxanes as neoadjuvant chemotherapy in breast cancer patients.Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mous FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma.Doxorubicin induced heart failure: Phenotype and molecular mechanisms.A rare case of the upper extremity diffuse large B-cell lymphoma mimicking soft tissue sarcoma in an elderly patient.PinX1-siRNA/mPEG-PEI-SPION combined with doxorubicin enhances the inhibition of glioma growth Do we still need chemotherapy for AIDS-associated Kaposi's sarcoma?Aptamer-Functionalized Nanoparticles as "Smart Bombs": The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment.Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines.TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis.Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity.Novel agents for the treatment of childhood leukemia: an update.Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model.Nanomedicinal products: a survey on specific toxicity and side effects.Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system.Liposomal anthracycline chemotherapy and the risk of second malignancies in patients with Kaposi's sarcoma (KS).Cardiotoxicity with carfilzomib at doses greater than 27 mg/m(2): A case series.The Use of Liposomes and Nanoparticles as Drug Delivery Systems to Improve Cancer Treatment in Dogs and Cats.Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma.Heparosan-coated liposomes for drug delivery.HIV-associated Kaposi's sarcoma in Maputo, Mozambique: outcomes in a specialized treatment center, 2010-2015.Aldose reductase inhibitor, fidarestat prevents doxorubicin-induced endothelial cell death and dysfunction.Riboflavin-containing telodendrimer nanocarriers for efficient doxorubicin delivery: High loading capacity, increased stability, and improved anticancer efficacy.PNC27 anticancer peptide as targeting ligand significantly improved antitumor efficacy of Doxil in HDM2-expressing cells.Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer Recent advances in "smart" delivery systems for extended drug release in cancer therapy

P2860

Q26823592-D28DF0B2-C2FA-41B9-A6EE-307317CF3EF0 Q26827175-28101827-AE90-40DE-BD60-BB88A8E8EA6B Q27027499-FC7D14D0-C1E0-4D80-824D-66C789A1F2FD Q28088315-73C1F3FB-CE08-40EE-A37C-CD8A64AD96C5 Q28396209-843579F1-1BA2-4750-85D7-43594C8DFF56 Q28397373-F99257DF-E71A-48FF-A07F-EDF8E9FE4E4C Q30251498-857E098F-7244-4636-9368-CCA6878D5D80 Q30399577-3C78E638-E461-4C97-915B-FE480F78C64F Q33418086-F849C559-5DB9-43FF-9B76-2A83988BE891 Q33634964-3FC98578-066B-4FD8-98B2-3C8CDB83DC73 Q33771516-37C7450B-6CFA-4365-A1AF-4569FE4F52BB Q34088194-B95810A8-D760-4B68-B932-DDD66405CF57 Q36912561-FE372551-77A7-4342-B6F4-EF3D411C73C1 Q37119773-CCFC9D32-F07E-498A-BA87-1A75AE6BD4A3 Q37710054-7FBA9B51-CF1A-4696-A16A-EBBA7B8215D1 Q38081246-B3026423-6327-4598-8FAA-E4CFB23B91DB Q38491805-EA85017B-5D90-4854-A91C-9D188A92E6AE Q38576762-64F4894A-D968-4F4E-94C8-0B567214BC04 Q38945753-066AB625-EE6A-4008-8439-71192CF9584F Q39264180-7F2C1863-7FA7-41D5-BD10-6041E8D52916 Q39455649-7D2D4C60-B2C2-48A1-BB27-BC7832001AC0 Q41493235-34B33D2E-2636-4B89-95B4-8260781A56A8 Q41545896-CD047432-BA45-4B6C-81CD-7EC67C6D79D5 Q41945537-16A1237A-EC67-489F-B43E-9A94B699E6E8 Q42204251-41A8A75A-255F-428D-8CC4-317218659F0C Q47980047-6EC71198-3DDB-4FA1-83C9-B98FAA0D6574 Q48160138-2B1B8CA0-2AB2-49B8-B972-2AF7D39EE177 Q48164881-42D3585D-3760-4D01-800E-AF18EA2F731D Q48627793-4D21C0AB-E1B2-46EF-B050-D1B592A32B46 Q49232494-A165C0E9-54BF-4C13-84DE-2D5FA85CC17C Q49848276-77B06FA6-89D7-428A-9FF6-69B40457A5BF Q50540851-966DDCB8-9F59-4331-A244-A01849175A24 Q50967733-4B89EAD1-16E2-4902-A72C-F0C7B3C3F490 Q54118354-7040A554-6D94-4D85-8F03-2B21396C006D Q57057499-A92E8B50-B24D-4547-B168-BE857C472D32 Q57106044-6351285D-34C9-428C-B1E0-D4ECEE255670 Q58735813-B5F5A389-9491-4923-B058-1A2863B922A6

P2860

Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis

http://www.wikidata.org/entity/Q33404677

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Comparison of safety and toxic ...... nthracyclines: a meta-analysis

@ast

Comparison of safety and toxic ...... nthracyclines: a meta-analysis

@en

type

label

Comparison of safety and toxic ...... nthracyclines: a meta-analysis

@ast

Comparison of safety and toxic ...... nthracyclines: a meta-analysis

@en

prefLabel

Comparison of safety and toxic ...... nthracyclines: a meta-analysis

@ast

Comparison of safety and toxic ...... nthracyclines: a meta-analysis

@en

P1433

Q33404677-B5EE5502-F37F-4E0D-ABEE-258E5D6C7D65

P1476

Q33404677-BC21996D-2E56-4E83-BC24-64085C1B8602

P2093

Q33404677-10886176-BED8-4016-AED3-30BB59DD4C2E

Q33404677-13524E8E-2D64-431A-B721-47DE89263BE4

Q33404677-372D5866-F67C-4C11-9813-3CA2357008E4

Q33404677-3AF77CBF-355A-4A3E-B88B-3F8933299455

Q33404677-C0ECE925-9EE0-4BA4-8570-E4F17607BEAB

Q33404677-F68608DD-F81E-410D-83AA-62679779851B

P2860

Q33404677-231CB77D-FC94-4EA4-80F6-3097D83B5C9C

Q33404677-2407C5F2-16A2-47FC-8BC5-BA9C7CF135AC

Q33404677-2711208B-D6D7-41E4-876C-F8A757EA72FD

Q33404677-36C6E071-CA39-474C-B5D2-FD19BC30B7CB

Q33404677-4A9598D8-4122-445A-A185-EF3CE49E1ED8

Q33404677-4FEBEAF0-23E0-45B9-9D7F-9BDECC41FF2A

Q33404677-5F267D27-E40E-404A-83A7-A4CA1E1AA02B

Q33404677-6E25B3AE-D810-4EB2-A6D9-02752C316F3E

Q33404677-77B3A1B9-2402-4906-96B3-1D29D8647A4D

Q33404677-7E34C633-161B-4113-B3AF-0E8A14B44ECF

P2888

Q33404677-6CF067D0-0D1B-42EB-9C42-77BD4CC9B3D8

P304

Q33404677-5D4B6A10-1A46-4255-A4F9-8D464C3B0B40

P31

Q33404677-3EF76708-1C5C-4CB8-A7FF-63ABB2C576E2

P356

Q33404677-496D5D9F-0AE8-4A78-BA46-EC46E52937EE

P433

Q33404677-AE5682EB-5598-451C-BBD8-EC238D7C2057

P478

Q33404677-B970F189-9079-4DBC-837D-E75222AF0A0F

P577

Q33404677-23DC05D1-43BA-4EA9-A535-C4242DBCD907

P5875

Q33404677-10F8CD3D-BA55-4226-86F4-C20CAD3CFC0E

P6179

Q33404677-CB80F86F-65AE-4581-B7C7-5623038AD72B

P698

Q33404677-6245AE9E-DD91-4E3E-BAAD-738E3CFEAA3B

P932

Q33404677-9257EC85-8C9B-439B-A0C9-D8A3686E54F3

P356

P1433

Experimental Hematology & Oncology

P1476

Comparison of safety and toxic ...... nthracyclines: a meta-analysis

@en

P2093

Byung Lee

http://www.w3.org/2001/XMLSchema#string

Delong Liu

http://www.w3.org/2001/XMLSchema#string

Guoqing Wei

http://www.w3.org/2001/XMLSchema#string

Gurpreet Lamba

http://www.w3.org/2001/XMLSchema#string

Mohammad Rasul

http://www.w3.org/2001/XMLSchema#string

Shamudheen M Rafiyath

http://www.w3.org/2001/XMLSchema#string

P2860

Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications

A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome

Risk factors for doxorubicin-induced congestive heart failure

Assessing heterogeneity in meta-analysis: Q statistic or I2 index?

Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.

Liposomal anthracyclines for breast cancer: overview.

P2888

P304

10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2162-3619-1-10

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233847500

http://www.w3.org/2001/XMLSchema#string

P6179

1030413235

http://www.w3.org/2001/XMLSchema#string

P698

23210520

http://www.w3.org/2001/XMLSchema#string

P932

3514106

http://www.w3.org/2001/XMLSchema#string